A Change In Big Pharma Response To FTC Delisting Warnings
The Federal Trade Commission continues to be concerned about improper patent listings in the U.S. Food and Drug Administration's Orange Book, their deterrence of generic entry, and their consequent impact on...To view the full article, register now.
Already a subscriber? Click here to view full article